NASDAQ:VRAY

ViewRay - VRAY Stock Forecast, Price & News

$3.36

0.00 (0.00%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $3.30
▼
$3.38
50-Day Range: $3.35
▼
$4.81
52-Week Range: $2.39
▼
$4.96

Volume: 792,670 shs
Average Volume: 1.37 million shs
Market Capitalization: $610.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.75

Institutional Ownership

ViewRay MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 100.9% Upside
$6.75 Price Target
Short Interest: Bearish
4.79% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.49
Upright™ Environmental Score
News Sentiment: 0.08
Based on 3 Articles This Week
Insider Trading: Selling Shares
$173,460 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.60) to ($0.49) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

426th out of 1,005 stocks

Electromedical Equipment Industry

7th out of 24 stocks

3.4

Analyst's Opinion

Consensus Rating
ViewRay has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.75, ViewRay has a forecasted upside of 100.9% from its current price of $3.36.
Amount of Analyst Coverage
ViewRay has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
4.79% of the outstanding shares of ViewRay have been sold short.
Short Interest Ratio / Days to Cover
ViewRay has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
Change versus previous month
Short interest in ViewRay has recently increased by 1.52%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
ViewRay does not currently pay a dividend.
Dividend Growth
ViewRay does not have a long track record of dividend growth.

5.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
ViewRay has received a 82.75% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "MRI machines", "Radiation therapy machines", and "Medical technology engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for ViewRay is -0.49.

1.7

News and Social Media Coverage

News Sentiment
ViewRay has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for ViewRay this week, compared to 2 articles on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ViewRay insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $173,460.00 in company stock.
Percentage Held by Insiders
Only 2.50% of the stock of ViewRay is held by insiders.
Percentage Held by Institutions
84.40% of the stock of ViewRay is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ViewRay are expected to grow in the coming year, from ($0.60) to ($0.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ViewRay is -5.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ViewRay is -5.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ViewRay has a P/B Ratio of 7.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ViewRay (NASDAQ:VRAY) Stock

ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

VRAY Stock News Headlines

March 23, 2023 | americanbankingnews.com

James F. Dempsey Sells 42,000 Shares of ViewRay, Inc. (NASDAQ:VRAY) Stock

March 18, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on ViewRay (NASDAQ:VRAY)

March 26, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

March 11, 2023 | finance.yahoo.com

ViewRay, Inc. (NASDAQ:VRAY) Q4 2022 Earnings Call Transcript

March 7, 2023 | finance.yahoo.com

Military University Hospital Prague Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Treat Cancer Patients

March 3, 2023 | msn.com

ViewRay Earnings Perspective: Return On Capital Employed

March 1, 2023 | finance.yahoo.com

ViewRay Full Year 2022 Earnings: EPS Beats Expectations

January 31, 2023 | finance.yahoo.com

ViewRay Announces Conference Call for Fourth Quarter 2022 Financial Results to be Held After Market on February 27, 2023

March 26, 2023 | Stansberry Research (Ad)

The gold catalyst we’ve waited for

If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.

January 12, 2023 | finance.yahoo.com

Findings Published in JAMA Oncology Demonstrate Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

January 9, 2023 | finance.yahoo.com

ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer

January 5, 2023 | finance.yahoo.com

Chindex Medical Acquires 10 ViewRay MRIdian® Systems for Advanced Cancer Treatment

December 27, 2022 | finance.yahoo.com

With 63% ownership, ViewRay, Inc. (NASDAQ:VRAY) boasts of strong institutional backing

November 30, 2022 | finance.yahoo.com

Susan Schnabel Just Bought 33% More Shares In ViewRay, Inc. (NASDAQ:VRAY)

November 24, 2022 | seekingalpha.com

ViewRay: Revise Thesis To Buy, Multiple Upside Targets In Place

November 15, 2022 | finance.yahoo.com

ViewRay Expands Access to Non-Dilutive Capital With New Debt Facility

November 14, 2022 | finance.yahoo.com

ViewRay® to Participate in the 34th Annual Piper Sandler Healthcare Conference

October 27, 2022 | finance.yahoo.com

MIRAGE Phase III Randomized Controlled Trial Demonstrates Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

October 25, 2022 | reuters.com

VRAY.OQ - Viewray Inc | Stock Price & Latest News | Reuters

October 24, 2022 | finance.yahoo.com

ViewRay Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

October 19, 2022 | finance.yahoo.com

MRIdian Clinical Studies and Initial MRIdian A3i Clinical Experience to be Highlighted at ASTRO 2022

October 18, 2022 | finance.yahoo.com

ViewRay Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

October 16, 2022 | finance.yahoo.com

ViewRay Announces Conference Call for Third Quarter 2022 Financial Results to be Held After Market on November 1, 2022 - Yahoo Finance

October 4, 2022 | finance.yahoo.com

San Pietro Fatebenefratelli Hospital Treats its 1,000th Patient with MRIdian® MRI-Guided Radiation Therapy

October 3, 2022 | benzinga.com

ViewRay to host Investor Day - ViewRay (NASDAQ:VRAY) - Benzinga

October 3, 2022 | finance.yahoo.com

ViewRay to host Investor Day

September 30, 2022 | businesswire.com

Insights on the Radiation Oncology Global Market to 2027 - Rapid Expansion of Cancer Research Centers Worldwide is Positively Influencing Growth - ResearchAndMarkets.com - Business Wire

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

VRAY Company Calendar

Last Earnings: 2/27/2023
Today: 3/26/2023
Next Earnings (Estimated): 5/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VRAY
CUSIP: N/A
CIK: 1597313
Web: www.viewray.com
Phone: (440) 703-3210
Fax: 800-417-3459
Employees: 267
Year Founded: 2004

Price Target and Rating

Average Stock Price Forecast: $6.75
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $5.50
Forecasted Upside/Downside: +100.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-107,330,000.00
Net Margins: -105.01%
Pretax Margin: -105.01%
Return on Equity: -93.57%
Return on Assets: -38.79%

Debt

Debt-to-Equity Ratio: 0.95
Current Ratio: 2.36
Quick Ratio: 2.04

Sales & Book Value

Annual Sales: $102.21 million
Price / Sales: 5.98
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.45 per share
Price / Book: 7.47

Miscellaneous

Outstanding Shares: 181,800,000
Free Float: 177,260,000
Market Cap: $610.85 million
Optionable: Optionable
Beta: 1.00

Social Links

Key Executives

Scott William Drake
President, Chief Executive Officer & Director

Drew Hill
Senior Vice President-Operations & Development

William Patrick Burke
Chief Financial Officer & Executive Vice President

James F. Dempsey
Chief Scientific Officer

Martin Fuss
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VRAY Stock - Frequently Asked Questions

Should I buy or sell ViewRay stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRAY shares.
View VRAY analyst ratings or view top-rated stocks.
What is ViewRay's stock price forecast for 2023?: 5 analysts have issued twelve-month price objectives for ViewRay's stock. Their VRAY share price forecasts range from $5.50 to $8.00. On average, they anticipate the company's share price to reach $6.75 in the next year. This suggests a possible upside of 100.9% from the stock's current price.
View analysts price targets for VRAY or view top-rated stocks among Wall Street analysts.
How have VRAY shares performed in 2023?: ViewRay's stock was trading at $4.48 on January 1st, 2023. Since then, VRAY shares have decreased by 25.0% and is now trading at $3.36.
View the best growth stocks for 2023 here.
When is ViewRay's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our VRAY earnings forecast.
How were ViewRay's earnings last quarter?: ViewRay, Inc. (NASDAQ:VRAY) announced its earnings results on Monday, February, 27th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01. The firm earned $34.70 million during the quarter, compared to analyst estimates of $34.65 million. ViewRay had a negative trailing twelve-month return on equity of 93.57% and a negative net margin of 105.01%. The company's revenue was up 70.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.16) earnings per share.
What ETFs hold ViewRay's stock?: ETFs with the largest weight of ViewRay (NASDAQ:VRAY) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC) and iShares U.S. Medical Devices ETF (IHI) and
What guidance has ViewRay issued on next quarter's earnings?: ViewRay updated its FY 2023 earnings guidance on Monday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $127.76 million-$143.09 million, compared to the consensus revenue estimate of $136.01 million.
What is Scott Drake's approval rating as ViewRay's CEO?: 5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ViewRay own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).
When did ViewRay IPO?: (VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.
What is ViewRay's stock symbol?: ViewRay trades on the NASDAQ under the ticker symbol "VRAY."
Who are ViewRay's major shareholders?: ViewRay's stock is owned by many different institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (9.19%), Neuberger Berman Group LLC (5.44%), Group One Trading L.P. (0.00%), Susquehanna International Group LLP (0.00%), Geode Capital Management LLC (1.50%) and Silverarc Capital Management LLC (1.33%). Insiders that own company stock include Brian K Roberts, Caley Castelein, Influence Ltd Strong, International Ltd Fosun, James F Dempsey, Scott William Drake, Susan C Schnabel and Zachary William Stassen.
View institutional ownership trends.
How do I buy shares of ViewRay?: Shares of VRAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ViewRay's stock price today?: One share of VRAY stock can currently be purchased for approximately $3.36.
How much money does ViewRay make?: ViewRay (NASDAQ:VRAY) has a market capitalization of $610.85 million and generates $102.21 million in revenue each year. The company earns $-107,330,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.
How many employees does ViewRay have?: The company employs 267 workers across the globe.
Does ViewRay have any subsidiaries?: The following companies are subsidiares of ViewRay: Vesuvius Acquisition Corp., ViewRay GmbH, and ViewRay Technologies Inc..
Read More
How can I contact ViewRay?: ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The official website for the company is www.viewray.com. The company can be reached via phone at (440) 703-3210, via email at investors@viewray.com, or via fax at 800-417-3459.

This page (NASDAQ:VRAY) was last updated on 3/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ViewRay - VRAY Stock Forecast, Price & News

ViewRay MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About ViewRay (NASDAQ:VRAY) Stock

VRAY Stock News Headlines

VRAY Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

VRAY Stock - Frequently Asked Questions

Overall MarketRank^™